. 2019 Apr 20;10(2):90–100. doi: 10.14740/wjon1193

Table 1. Baseline Characteristics, Treatment, and Laboratory Data According to GRIm-Score (N = 76).

N	GRIm-Score		P
N	Low (N = 55)	High (N = 21)	P
Backgrounds
Sex (N)
Male/female	35/20	14/7	1.00^a
Age (years)
Median (IQR)	69 (62.5 - 73)	71 (68 - 75)	0.29^b
Smoking status (N)
NS/Ex, CS	12/43	4/17	1.00^a
BMI
Median (IQR)	22.7 (21.0 - 25.1)	22.5 (18.2 - 24.0)	0.26^b
≥ 18.5/< 18.5 (N)	48/7	14/7	0.051^a
Histology (N)
Non-SQ/SQ	42/13	16/5	1.00^a
EGFR mutation (N)
(-) or NA/(+)	46/9	19/2	0.72^a
PD-L1 status (N)
≥ 50%/1-49%/< 1% /NA	13/9/5/28	1/5/3/11	0.25^a
ECOG-PS (N)
0-1/2/3	43/11/1	11/6/4	0.02^a
Metastatic sites (N)
< 3/≥ 3	25/30	10/11	1.00^a
Treatment
ICI regimen (N)
Nivolumab	41	17
Pembrolizumab	11	2
Atezolizumab	3	2	0.08^a
Previous treatment (N)
Anti-angiogenic drug	25	11	0.62^a
EGFR-TKIs	13	2	0.21^a
Radiotherapy	13	6	0.77^a
Further line treatment (N)	31	9	0.32^a
ICI efficacy
ORR (%) (95% CI)	18.2 (9.1 - 30.9)	4.8 (0.1 - 23.8)	0.27^a
DCR (%) (95% CI)	41.8 (28.7 - 55.9)	19.0 (5.4 - 41.9)	0.11^a
Laboratory data
NLR
Median (IQR)	2.64 (1.89 - 3.89)	5.85 (3.57 - 7.18)	< 0.01^b
> 6 (N)	1	10	< 0.01^a
LDH (U/L)
Median (IQR)	208 (184.5 - 242.5)	324 (228 - 387)	< 0.01^b
> ULN (N)	19	16	< 0.01^a
Albumin (g/dL)
Median (IQR)	3.8 (3.5 - 4.0)	3.1 (2.8 - 3.2)	< 0.01^b
< 3.5 g/dL (N)	9	21	< 0.01^a

^aFisher’s exact test, ^bMann-Whitney U test. BMI: body mass index; CI: confidence interval; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; GRIm-Score: Gustave Roussy Immune Score; IQR: interquartile range; ICI: immune-checkpoint inhibitor; LDH: lactate dehydrogenase; NA: not assessed; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; SQ; squamous cell carcinoma; TKI: tyrosine kinase inhibitor; ULN: upper limit of normal.